Formycon AG(FYB)

Description: Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company's pipeline includes FYB202, a biosimilar candidate for Stelara used in the treatment of Psoriasis, Crohn's disease, and ulcerative colitis which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea that treats ophthalmology related diseases, including neovascular age-related macular degeneration that has completed Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of immuno-oncology diseases; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

---

Keywords: Biotechnology Monoclonal Antibodies Psoriasis Ulcerative Colitis Macular Degeneration Diabetic Retinopathy Crohn's Disease Biosimilar Blindness Macular Edema Retinopathy Diabetic Macular Edema Treatment Of Psoriasis Aflibercept Angiogenesis Inhibitors Ranibizumab Eylea Lucentis Stelara Neovascular Age Related Macular Degeneration Fyb206 Proliferative Diabetic Retinopathy Serious Retinal Diseases

---

Home Page: www.formycon.com

Fraunhoferstrasse 15
Planegg, 82152
Germany
Phone: 49 89 864 667 100

---

Officers

Exchange: XETRA

Country: DE : Germany

Currency: Euro (€)